JTE-013

Name: JTE-013
Brand: DC Chemicals
SKU: DC10607
Price: 450.0 USD

Pack size & price

USD

Ready-made solution

Total$450

We match the best price and quality on market.

Product overview

Description & Application

JTE-013 is an S1PR2 antagonist used in sphingosine-1-phosphate signaling, mitochondrial dynamics and fibrosis research.

Parameter	Value
Chemical Name	Pyrazolopyridine analog
CAS No.	383150-41-2
Synonyms	1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea; JTE-013; Jte 013; S1P2 Receptor Antagonist, JTE-013; 1-(1,3-Dimethyl-4-isopropyl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-(3,5-dichloro-4-pyridinyl)-semicarbazide; pyrazolopyridine analog; CTK8F0047; MolPort-003-983-772; HMS3269A03; 1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(2,6-dichloro-4-pyridinyl)-semicarbazide; N-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-hydrazinecarboxamide; N-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide; C17H19Cl2N7O; GTPL2917; AOB1935; SYN5010; HMS3413I20; HMS3650O1
Formula	C17H19Cl2N7O
M.Wt	408.2851
SMILES	ClC1C([H])=C(C([H])=C(N=1)Cl)N([H])C(N([H])N([H])C1C([H])=C(C2C(C([H])([H])[H])=NN(C([H])([H])[H])C=2N=1)C([H])(C([H])([H])[H])C([H])([H])[H])=O
Purity	>98%
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

S1PR2-associated signaling · Literature evidence

Biological Activity

JTE-013 is an S1PR2 antagonist used in sphingosine-1-phosphate signaling, mitochondrial dynamics and fibrosis research. Reduced RHOA/TAZ and CTGF/CYR61 signaling; phosphorylated YAP and Lats1 increased.

In Vitro

Endpoint	Model / conditions / source	Reported result
Epithelial signaling	MLE-12 cells; JTE-013 2 µM for 2 h before S1P 3 µM for 24 h. [1], Methods and Figs. 4–6	Reduced RHOA/TAZ and CTGF/CYR61 signaling; phosphorylated YAP and Lats1 increased.
Fibrosis and mitochondria	S1P-challenged MLE-12 cells. [1]	Lower α-SMA, COL1A1 and MMP-9 accompanied changes in Drp1-associated mitochondrial dynamics and reduced oxidative stress.

In Vivo

Endpoint	Model / conditions / source	Reported result
Exposure and model	Bleomycin lung-fibrosis mouse model; JTE-013 8 mg/kg intraperitoneally on days 1, 3 and 5; n=10 per group. [1], Methods	Lung inflammation and fibrosis were assessed on days 7 and 28.
Lung outcomes	Histology, collagen staining and bronchoalveolar inflammatory markers. [1], Figs. 1–3	JTE-013 reduced inflammatory infiltration and fibrosis-related changes. Verteporfin co-treatment reversed several measured effects.